At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Ranibizumab 2 mg +1 moredrug
Likely dose
Ranibizumab 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma
In Brief
A Phase 2 clinical trial evaluating Ranibizumab 2 mg and 0.5 mg Ranibizumab for Choroidal Melanoma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Melanoma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedDec 2010
Primary CompletionJul 2012
Study CompletionAug 2012
TodayJul 2026
First PostedDec 2, 2010
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.6 years ago
Interventions
Ranibizumab 2 mgdrug
intravitreal injections of ranibizumab once a month, times 3.
0.5 mg Ranibizumabdrug
6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.